ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA
Enrolling By Invitation
18 years - 99 years
All
Phase
N/A
10 participants needed
1 Location
Brief description of study
Purpose is to determine if cemiplimab (given as infusion in the vein) will prevent cutaneous squamous cell cancer from returning after surgery and radiation. Subjects at least 18 years of age who have had surgery and radiation therapy for cutaneous squamous cell cancer, and there is a risk that this cancer may come back.
Procedures include Vital signs, Physical Exam, Height and Weight, Medical History, Blood and Urine tests, CT scans, MRI, EKG, Skin biopsies and subject questionnaires
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: squamous cell cancer,cancer
-
Age: 18 years - 99 years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 833454
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
